Amgen (AMGN) announced plans to invest more than $600M in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Veeva’s Clinical Platform selected by Amgen
- Amgen’s Repatha: Balancing Growth Potential with Long-Term Risks
- Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen
- Amgen says FDA broadens the approved use of Repatha
- Amgen price target raised to $342 from $328 at Piper Sandler